CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

Core Insights - CorMedix Inc. will report its financial results for Q3 2025 on November 12, 2025, before market opens and will host a conference call at 8:30 AM ET [1] - The company focuses on developing therapeutic products for life-threatening diseases, including its commercialized product DefenCath for preventing catheter-related bloodstream infections [3] Company Overview - CorMedix is a biopharmaceutical company that has commercialized DefenCath (taurolidine and heparin) for adult patients undergoing hemodialysis [3] - Following the acquisition of Melinta Therapeutics in August 2025, CorMedix is also marketing a range of anti-infective products, including MINOCIN®, REZZAYO®, VABOMERE®, ORBACTIV™, BAXDELA®, and KIMYRSA® [3] Clinical Studies and Developments - Ongoing clinical studies for DefenCath include applications in Total Parenteral Nutrition and pediatric populations, with plans to develop it as a catheter lock solution for other patient groups [4] - REZZAYO is approved for treating candidemia and invasive candidiasis in adults, with a Phase III study for prophylaxis of invasive fungal disease (IFD) in adult patients undergoing allogeneic bone marrow transplantation, with topline results expected in Q2 2026 [4]